Celldex Therapeutics (NASDAQ:CLDX) Announces Quarterly Earnings Results

Celldex Therapeutics (NASDAQ:CLDX) released its quarterly earnings results on Wednesday. The biopharmaceutical company reported ($1.22) EPS for the quarter, missing the consensus estimate of ($1.00) by ($0.22), FiscalAI reports. The business had revenue of $0.12 million for the quarter, compared to analysts’ expectations of $1.53 million. Celldex Therapeutics had a negative net margin of 3,446.88% and a negative return on equity of 33.22%.

Celldex Therapeutics Trading Down 0.6%

Shares of CLDX traded down $0.18 during trading hours on Thursday, reaching $30.64. 1,673,058 shares of the stock traded hands, compared to its average volume of 789,878. The company has a market cap of $2.04 billion, a P/E ratio of -9.07 and a beta of 1.24. The company’s 50-day moving average price is $25.61 and its two-hundred day moving average price is $25.43. Celldex Therapeutics has a 52-week low of $14.40 and a 52-week high of $31.31.

Hedge Funds Weigh In On Celldex Therapeutics

Several large investors have recently made changes to their positions in CLDX. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Celldex Therapeutics by 1.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,451 shares of the biopharmaceutical company’s stock worth $798,000 after purchasing an additional 680 shares in the last quarter. Millennium Management LLC boosted its stake in Celldex Therapeutics by 327.3% in the 1st quarter. Millennium Management LLC now owns 399,932 shares of the biopharmaceutical company’s stock worth $7,259,000 after purchasing an additional 306,330 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in Celldex Therapeutics by 12.9% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 131,296 shares of the biopharmaceutical company’s stock worth $2,383,000 after purchasing an additional 14,979 shares during the period. Russell Investments Group Ltd. grew its holdings in Celldex Therapeutics by 27.6% during the 2nd quarter. Russell Investments Group Ltd. now owns 2,315 shares of the biopharmaceutical company’s stock valued at $47,000 after buying an additional 501 shares in the last quarter. Finally, Hsbc Holdings PLC bought a new stake in shares of Celldex Therapeutics during the second quarter valued at approximately $347,000.

More Celldex Therapeutics News

Here are the key news stories impacting Celldex Therapeutics this week:

• Positive Sentiment: Completed enrollment in global Phase 3 EMBARQ program (EMBARQ‑CSU1 & EMBARQ‑CSU2) for barzolvolimab — 1,939 patients across 43 countries, the largest antihistamine‑refractory CSU program, which de‑riscales the timeline for potential 2026 data readouts. Completion of Phase 3 Enrollment
• Positive Sentiment: Analysts showing conviction: Stifel Nicolaus reaffirmed a Buy and raised its price target to $68 (previously $58) — implying ~122% upside from the current price level — which can support investor interest and buying pressure. Stifel Rating/Price Target
• Positive Sentiment: Morgan Stanley (via TipRanks summary) and other analysts have reiterated Buy ratings, citing early EMBARQ enrollment and multiple 2026 data catalysts that improve the risk/reward profile. Analyst Commentary
• Neutral Sentiment: Consensus on analyst coverage is mixed‑to‑positive — sites report an average rating around “Moderate Buy,” which supports a constructive medium‑term view but is not a unanimous bullish signal. Analyst Consensus
• Neutral Sentiment: Short interest reporting appears anomalous / immaterial in recent data (reported as zero), so it likely did not meaningfully influence today’s move. Short Interest Note
• Negative Sentiment: Q4 2025 results missed expectations: CLDX reported ($1.22) EPS vs. ($1.00) consensus and revenue of $0.12M vs. $1.53M expected — the miss increases near‑term financial uncertainty and likely drove intraday selling pressure despite the clinical progress. Earnings Press Release

Wall Street Analysts Forecast Growth

A number of brokerages have commented on CLDX. Stifel Nicolaus reaffirmed a “buy” rating and set a $68.00 target price (up from $58.00) on shares of Celldex Therapeutics in a report on Thursday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Celldex Therapeutics in a report on Wednesday, January 21st. Finally, Barclays boosted their price target on Celldex Therapeutics from $21.00 to $24.00 and gave the company an “underweight” rating in a report on Wednesday, December 17th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, Celldex Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $44.20.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.